Drug Approval | November 09, 2023
Lupin launches Rocuronium Bromide injection in US
Rocuronium Bromide Injection had estimated annual sales of USD 54 million in the US (IQVIA MAT August 2023).
Rocuronium Bromide Injection had estimated annual sales of USD 54 million in the US (IQVIA MAT August 2023).
Total transaction value of the divestment is Rs. 3,660 million
The agreement demonstrates a shared commitment to advance precision medicine and improve patient outcomes in the region
In 2022, darolutamide was FDA-approved in combination with docetaxel chemotherapy for adults with metastatic hormone-sensitive prostate cancer
This project will aim to develop a next-generation A3 adenosine receptor drug agonists
Zydus will pay an upfront consideration of GBP 68 million and yearly earn-outs until 2026
Aster Whitefield will be Aster's 3 rd multi-specialty hospital in Bengaluru and overall 19th hospital in India
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
Subscribe To Our Newsletter & Stay Updated
